4-methoxy-2,2,6,6-tetramethylpiperidine | 26275-90-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-methoxy-2,2,6,6-tetramethylpiperidine
• CAS: 26275-90-1
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: RWWGPCWSFFOXJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methoxy-2,2,6,6-tetramethylpiperidine 在 双氧水 作用下， 以 甲醇 为溶剂， 以98.5 %的产率得到4-甲氧基-四甲基哌啶氧自由基
  参考文献：
  名称：

  CN116063224

  摘要：

  公开号：

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S
  申请人：NOVARTIS AG

  公开号：WO2006018284A1

  公开（公告）日：2006-02-23

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式(I)的2-氰基嘧啶化合物，其中R1、R2、R3和X如规范和权利要求中定义的那样，以自由形式或盐形式，并在可能的情况下以互变异构形式，作为猫hepsin S活性的抑制剂。
• [EN] N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] N-(4-(AZAINDAZOL-6-YL)PHÉNYL)SULFONAMIDES ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2014140065A1

  公开（公告）日：2014-09-18

  N-(4-(Azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及公式I的N-(4-(吡唑吲唑-6-基)-苯基)-磺酰胺，其中Ar、n、X、Z、R1、R2和R3具有索引中指示的含义。公式I的化合物是有价值的药理活性化合物，可以调节蛋白激酶活性，特别是血清和糖皮质激素调节激酶（SGK）的活性，特别是血清和糖皮质激素调节激酶同工酶1（SGK-1，SGK1）的活性，并适用于治疗SGK活性不当的疾病，例如退行性关节疾病或炎症过程，如骨关节炎或风湿病。本发明还涉及公式I的化合物的制备方法，它们作为药物的用途，以及包含它们的药物组合物。
• MODIFIED ZNO NANOPARTICLES
  申请人：Riggs Richard

  公开号：US20120097068A1

  公开（公告）日：2012-04-26

  Process for the preparation of modified zinc oxide nanoparticles, which comprises reacting zinc oxide nanoparticles, which are dissolved in a solvent, in the presence of ammonia or amines with a tetraalkyl orthosilicate and optionally with an organosilane, with the proviso that the reaction takes place at a content of less than 5% by weight of water, based on the total amount of solvent and water. Modified zinc oxide nanoparticles which have Si—O-alkyl groups and are soluble in organic solvents, obtainable by this process for the preparation. Liquid or solid formulations which comprise modified ZnO nanoparticles. Inanimate organic materials, for example plastics or coatings, which comprise modified ZnO nanoparticles. Method of stabilizing inanimate organic materials against the effect of light, free radicals or heat, where modified ZnO nanoparticles, which optionally comprise UV absorbers and/or stabilizers as further additives, are added to the materials.

  制备改性氧化锌纳米颗粒的过程包括在溶剂中溶解的氧化锌纳米颗粒与氨或胺在场的情况下，与四烷基正硅酸酯和可选的有机硅烷反应，但反应需在溶剂和水的总量中水含量低于5%的条件下进行。通过该制备过程可获得具有Si-O-烷基基团且可溶于有机溶剂的改性氧化锌纳米颗粒。包含改性ZnO纳米颗粒的液体或固体配方。包含改性ZnO纳米颗粒的无机有机材料，例如塑料或涂料。一种稳定无机有机材料抵抗光线、自由基或热效应的方法，其中将改性ZnO纳米颗粒添加到材料中，这些纳米颗粒可包含紫外吸收剂和/或稳定剂作为进一步添加剂。
• CONTINUOUS PROCESS FOR PREPARING (METH)ACRYLATES OF C10- ALCOHOL MIXTURES
  申请人：BASF SE

  公开号：US20140135523A1

  公开（公告）日：2014-05-15

  A continuous process for preparing (meth)acrylates of C 10 -alcohol mixtures by reaction of glacial (meth)acrylic acid with an isomer mixture of C 10 -alcohols composed of 2-propylheptanol as the main isomer and at least one of the C 10 -alcohols 2-propyl-4-methylhexanol, 2-propyl-5-methylhexanol, 2-isopropylheptanol, 2-isopropyl-4-methylhexanol, 2-isopropyl-5-methylhexanol and/or 2-propyl-4,4-dimethylpentanol, and the use of a diester of dicarboxylic acids which have been esterified with N-oxyl-containing compounds as polymerization inhibitors in such a process.

  通过将冰冷的（甲基）丙烯酸与由2-丙基庚醇异构体混合物反应制备C10-醇混合物的（甲基）丙烯酸酯的连续过程，其中以2-丙基庚醇为主要异构体，至少包括以下C10-醇之一：2-丙基-4-甲基己醇，2-丙基-5-甲基己醇，2-异丙基庚醇，2-异丙基-4-甲基己醇，2-异丙基-5-甲基己醇和/或2-丙基-4,4-二甲基戊醇，并在这种过程中使用已与含N-氧基的化合物酯化的二羧酸二酯作为聚合抑制剂。
• COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM
  申请人：MERCK PATENT GMBH

  公开号：US20180216005A1

  公开（公告）日：2018-08-02

  Compounds of the formula I, and liquid-crystalline media, preferably having a nematic phase and negative dielectric anisotropy, comprising a) one or more compounds of the formula I and one or more compounds selected from b) one or more compounds of formula II and/or c) one or more compounds selected from compounds of formulae III-1 to III-4 and formula B Methods for making and using these liquid-crystalline media in electro-optical displays, particularly in active-matrix displays based on the VA, ECB, PALC, FFS or IPS effect and the displays which contain these media. Methods for stabilizing liquid-crystalline media with compounds of formula I, where the liquid-crystalline media comprise one or more compounds of the formula II and one or more compounds selected from compounds of the formulae III-1 to III-4 and formula B.

  公式I的化合物和液晶介质，最好具有向列相和负介电各向异性，包括a) 一个或多个公式I的化合物和一个或多个选自b) 一个或多个公式II的化合物和/或c) 一个或多个选自公式III-1至III-4和公式B的化合物的液晶介质的方法。制备和使用这些液晶介质的方法在电光显示中，特别是基于VA、ECB、PALC、FFS或IPS效应的主动矩阵显示和包含这些介质的显示器。一种使用公式I的化合物稳定液晶介质的方法，其中液晶介质包括一个或多个公式II的化合物和一个或多个选自公式III-1至III-4和公式B的化合物。